292 related articles for article (PubMed ID: 28834694)
21. Case report: Optimized ruxolitinib-based therapy in an infant with familial hemophagocytic lymphohistiocytosis type 3.
Niizato D; Isoda T; Mitsuiki N; Kaneko S; Tomomasa D; Kamiya T; Takagi M; Imai K; Kajiwara M; Shimizu M; Morio T; Kanegane H
Front Immunol; 2022; 13():977463. PubMed ID: 36505485
[TBL] [Abstract][Full Text] [Related]
22. A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature.
Irino K; Jinnouchi F; Nakano S; Sawabe T
Clin Rheumatol; 2023 Jul; 42(7):1959-1963. PubMed ID: 36947281
[TBL] [Abstract][Full Text] [Related]
23. Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.
Huang Z; Xie J
Medicine (Baltimore); 2021 Mar; 100(11):e25188. PubMed ID: 33726009
[TBL] [Abstract][Full Text] [Related]
24. Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib.
Fuchs A; Orth HM; Germing U; Kondakci M; Holtfreter M; Feldt T; Jensen BE; Häussinger D
Int J Infect Dis; 2020 Nov; 100():382-385. PubMed ID: 32777582
[TBL] [Abstract][Full Text] [Related]
25. Rituximab, etoposide, methylprednisolone, high-dose cytarabine, and cisplatin in the treatment of secondary hemophagocytic lymphohistiocytosis with classical Hodgkin lymphoma: a case report and review of the literature.
Hu S; Bansal P; Lynch D; Rojas Hernandez CM; Dayao Z
J Med Case Rep; 2016 Dec; 10(1):365. PubMed ID: 27998299
[TBL] [Abstract][Full Text] [Related]
26. JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition.
Chaturvedi V; Lakes N; Tran M; Castillo N; Jordan MB
Blood; 2021 Sep; 138(12):1034-1039. PubMed ID: 34232994
[TBL] [Abstract][Full Text] [Related]
27. Profile of hemophagocytic lymphohistiocytosis; efficacy of intravenous immunoglobulin therapy.
Rajajee S; Ashok I; Manwani N; Rajkumar J; Gowrishankar K; Subbiah E
Indian J Pediatr; 2014 Dec; 81(12):1337-41. PubMed ID: 24806152
[TBL] [Abstract][Full Text] [Related]
28. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis.
Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y
Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611
[TBL] [Abstract][Full Text] [Related]
29. Cellular and transcriptional impacts of Janus kinase and/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis.
Albeituni S; Oak N; Tillman HS; Stroh A; Keenan C; Bloom M; Nichols KE
Front Immunol; 2023; 14():1137037. PubMed ID: 37228616
[TBL] [Abstract][Full Text] [Related]
30. Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis.
Song Y; Li X; He X; Zhou F; Du F; Wang Z; Chen S; Wu D
Front Immunol; 2023; 14():1211655. PubMed ID: 37457729
[TBL] [Abstract][Full Text] [Related]
31. Hemophagocytic lymphohistiocytosis associated with acute otitis media: A case report.
Chung DH; Lee KY; Kim JY; Jung DJ
Medicine (Baltimore); 2024 Jun; 103(25):e38616. PubMed ID: 38905364
[TBL] [Abstract][Full Text] [Related]
32. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D
Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment of hemophagocytic lymphohistiocytosis in a patient with systemic lupus erythematosus with ruxolitinib: a case report.
Jung JI; Kim JY; Kim MH; Park JK; Lee EY; Lee EB; Park JW
J Rheum Dis; 2024 Apr; 31(2):125-129. PubMed ID: 38559795
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children*.
Rajasekaran S; Kruse K; Kovey K; Davis AT; Hassan NE; Ndika AN; Zuiderveen S; Birmingham J
Pediatr Crit Care Med; 2014 Jun; 15(5):401-8. PubMed ID: 24583503
[TBL] [Abstract][Full Text] [Related]
35. Hemophagocytic lymphohistiocytosis after COVID-19 vaccination.
Tang LV; Hu Y
J Hematol Oncol; 2021 Jun; 14(1):87. PubMed ID: 34088334
[TBL] [Abstract][Full Text] [Related]
36. Adjustments to pharmacologic therapies for hemophagocytic lymphohistiocytosis while on extracorporeal support.
Weyand AC; Barbaro RP; Walkovich KJ; Frame DG
Pediatr Blood Cancer; 2021 Jun; 68(6):e29007. PubMed ID: 33751818
[TBL] [Abstract][Full Text] [Related]
37. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Harrison C; Kiladjian JJ; Al-Ali HK; Gisslinger H; Waltzman R; Stalbovskaya V; McQuitty M; Hunter DS; Levy R; Knoops L; Cervantes F; Vannucchi AM; Barbui T; Barosi G
N Engl J Med; 2012 Mar; 366(9):787-98. PubMed ID: 22375970
[TBL] [Abstract][Full Text] [Related]
38. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: what is the treatment?
Demirkol D; Yildizdas D; Bayrakci B; Karapinar B; Kendirli T; Koroglu TF; Dursun O; Erkek N; Gedik H; Citak A; Kesici S; Karabocuoglu M; Carcillo JA;
Crit Care; 2012 Dec; 16(2):R52. PubMed ID: 22715953
[TBL] [Abstract][Full Text] [Related]
39. Two-faced haemophagocytic lymphohistiocytosis: comparative review of two cases of adult haemophagocytic lymphohistiocytosis.
Mayson E; Saverimuttu J; Warburton P
Intern Med J; 2014 Feb; 44(2):198-201. PubMed ID: 24528817
[TBL] [Abstract][Full Text] [Related]
40. Ruxolitinib.
Becker H; Engelhardt M; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
